Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eagle Pharmaceuticals 50 TICE BOULEVARD SUITE 315 WOODCLIFF LAKE NJ 07677 USA

P: 201-326-5300

Description:

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 350,989
Enterprise Value, $K 278,939
Shares Outstanding, K 13,285
Annual Sales, $ 171,550 K
Annual Net Income, $ -8,630 K
Last Quarter Sales, $ 74,140 K
Last Quarter Net Income, $ -9,450 K
60-Month Beta 0.66
% of Insider Shareholders 28.20%
% of Institutional Shareholders 88.49%
Float, K 9,539
% Float 71.80%
Short Volume Ratio 0.81

Growth:

1-Year Return -52.64%
3-Year Return -55.27%
5-Year Return -54.64%
5-Year Revenue Growth -9.46%
5-Year Earnings Growth -113.31%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.56 on 08/09/22
Next Earnings Date 11/08/22
Earnings Per Share ttm 1.76
EPS Growth vs. Prev Qtr -121.70%
EPS Growth vs. Prev Year -374.07%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EGRX Ratios

Ratio
Price/Earnings ttm 16.25
Price/Earnings forward 9.93
Price/Earnings to Growth N/A
Return-on-Equity % 11.18%
Return-on-Assets % 7.52%
Profit Margin % -5.03
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 2.21
Price/Cash Flow N/A
Price/Book 1.53
Book Value/Share 18.68
Interest Coverage -1.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar